Reverse-Switching OTC Antimicrobials Could Cost Europe An Additional €10bn Per Year

 
• By David Ridley
  
AR
European policy targeting AMR could be very costly • Source: Shutterstock
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Europe

More from ESG